A University of Texas at San Antonio researcher has developed a molecular smart probe designed to make aggressive triple-negative breast cancer cells glow during operations. The technology addresses the challenge of identifying microscopic tumor margins in real time to lower recurrence risks.
Fluorescent Probe Helps Surgeons Identify Residual Cancer Cells
- Cleaner Surgical Margins: The fluorescent probe illuminates residual cancer cells directly in the operating room, helping surgeons distinguish malignant tissue from healthy areas.
- Targeting the Inside of Cells: Rather than searching for surface receptors, the probe binds to internal growth proteins called cyclin-dependent kinases 4 and 6 (CDK 4/6) which are often overexpressed in aggressive tumors.
- Smart Activation Mechanism: Unlike conventional imaging dyes that stay constantly lit, this probe remains dark in healthy tissue and switches on only when it locks onto its target protein.
Overcoming Blind Spots in Triple-Negative Breast Cancer Surgery
Surgical removal remains the primary intervention for more than half of all cancer patients every year. However, in structurally erratic cancers like triple-negative breast cancer, finding the exact boundary between the tumor and healthy tissue is a major clinical challenge. Relying solely on sight and touch leaves open the possibility of leaving behind microscopic clusters of residual cells, which significantly elevates the risk of the disease returning and spreading through the body.
Triple-negative breast cancer constitutes roughly 15% to 20% of all breast cancer cases. The subtype is defined by the absence of three standard receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Because standard targeted therapies and hormone treatments rely on these receptors, this specific form of cancer is resistant to many first-line interventions.
Fluorescence-guided surgery is an emerging approach that injects patients with targeted fluorescent dyes, known as fluorophores, before an operation. Specialized near-infrared lasers then illuminate these dyes to create a glowing map of the tumor. Unfortunately, conventional fluorescent dyes also require those missing receptors to bind effectively.
Engineering an Intelligent Warning Light
Syed Muhammad Usama, assistant professor of chemical biology in the Department of Chemistry at the UT San Antonio College of Sciences, took a different approach by targeting intracellular proteins. His laboratory focuses on cyclin-dependent kinases 4 and 6 (CDK 4/6), proteins that help fuel tumor growth from inside the cell and are produced in high quantities by most triple-negative breast cancer tumors.
To target these proteins, the research team paired an FDA-approved drug called palbociclib—which naturally binds to CDK 4/6—with a deep-tissue-penetrating near-infrared fluorogenic dye called cyclizing heptamethine cyanine (c-Cy7) developed by Usama. Together, the two compounds form a smart probe designated as c-Cy7-pal.
Traditional imaging dyes are constantly active, creating background noise when the dye pools in healthy tissue. By contrast, the c-Cy7-pal probe functions through a switch-flipping activation mechanism. While traveling through healthy tissue, the probe naturally twists into a closed, dark state. When it penetrates a cancer cell and binds to the targeted CDK 4/6 protein, a shift in internal chemistry and polarity causes the molecule to snap open into a charged, fluorescent state.
| Probe Component | Classification | Primary Function |
|---|---|---|
| Palbociclib (pal) | FDA-approved drug | Naturally binds to CDK 4/6 intracellular proteins |
| c-Cy7 | Near-infrared fluorogenic dye | Provides deep-tissue penetration and fluorescence |
| c-Cy7-pal | Smart molecular probe | Illuminates malignant tissue while remaining dark elsewhere |
Voelcker Fund Provides Financial Backing for Research
The clinical potential of the project has earned financial backing from the Max and Minnie Tomerlin Voelcker Fund, including a recent award of $450,000. This funding is designed to accelerate the research from basic organic chemistry into translational models that could reshape surgical oncology.
In addition to advancing surgical technology, the Voelcker Fund Young Investigator Award supports educational training. Usama has integrated five PhD students and 12 undergraduate students into the laboratory, involving them in chemistry, biochemistry, biology, and biomedical engineering work. The initiative includes redesigned junior-level biochemistry coursework and a specialized graduate-level chemical biology course.
Probe Remains in Research Phase and Unavailable for Care
Because the c-Cy7-pal probe is currently in the translational research phase and has not yet completed broad human clinical trials, it is not available for standard patient care. Patients diagnosed with triple-negative breast cancer should consult their oncologists and surgical teams regarding currently approved diagnostic tools, standard surgical margins, and active clinical trial enrollments.
Individuals experiencing new or persistent post-surgical symptoms—such as localized pain, unusual swelling, palpable lumps near the surgical site, or systemic signs of recurrence—should immediately contact their treating physician or surgical oncologist for formal evaluation.
References
- University of Texas at San Antonio
